TRIUMPH-1 studied adults with obesity without diabetes. Other parts of the retatrutide program include adults with type 2 diabetes, often under separate trial protocols.
Population eligibility changes interpretation
Baseline metabolic health and concurrent treatments can differ between these studies. Results can therefore vary for reasons beyond the investigational medicine itself.
How to interpret the evidence
Look for the diabetes eligibility criterion before comparing percentages or discussing applicability. Use the study population as part of the result label.
Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.